This medtech stock has a ‘pathway to $1B in sales’ by 2030, Piper Sandler says

[ad_1] It’s time to buy Glaukos ahead of some “exciting” product launches, Piper Sandler said. Analyst Matt O’Brien upgraded Glaukos to overweight, saying investors are overlooking the potential in its treatments for glaucoma, corneal disorders and retinal diseases, namely iDose and iStent. “While the name has run in recent weeks following iDose NDA submission, we…

Read More